MANAGEMENT REPORT Consolidated net sales for Q3 2025 were € 1.99 million, which was a 2.5% increase compared to the same period last year (Q3 2024: € 1.94 million). Nordic Fibreboard`s sales revenue Q3 2025 was generated from the Group`s main activity, which is the production and wholesale of fibreboard. The consolidated EBITDA of Nordic Fibreboard for Q3 2025 was positive € 94 thousand, the EBITDA margin was positive 5% (Q3 2024: EBITDA was negative € 19 thousand, and the EBITDA margin was negative 1%). Co ...

According to preliminary unaudited data, AB “Pieno žvaigždės” sales revenue for the first nine months of 2025 was EUR 167.5 million, or 5.2% higher than a year earlier (nine-month sales revenue in 2024 was EUR 159.2 million). EBITDA for the first nine months of 2025 was EUR 10.9 million, compared to EBITDA of EUR 16.7 million a year ago. In the first nine months of 2025, the company generated a net profit of EUR 5.7 million. In the first nine months of 2024, the company had generated a net profit of EUR 11. ...

(Selskabsmeddelelse 21/2025) De tekniske udfordringer er nu løst. Derfor anmoder vi om ophør af suspension af alle afdelinger. Med venlig hilsen Syd Fund Management A/S Tlf. 74 37 33 00 ...

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- As electric vehicle adoption accelerates in the United States and around the world, home charging has become one of the most important considerations for new and existing EV owners. Today, EVDANCE, a leading provider of portable EV charging equipment, announced its official 2025 Home EV Charger Recommendations, emphasizing two key priorities for consumers: UL2594 safety-certified chargers and a major Black Friday promotion offering 20% off plus a free adapter. Wit ...

The membership of the Supervisory Board of Aktsiaselts Infortar subsidiary AS Elenger Grupp is changing. As of December, 1 2025 Priit Tamme is appointed as a member Supervisory Board based on a resolution of the sole shareholder of AS Elenger Grupp. The Supervisory Board of AS Elenger Grupp will continue with five members. Infortar operates in seven countries. the company's main fields of activity are maritime transport. energy and real estate. Infortar owns a 68.47% share in Tallink Grupp. a 100% share in ...

Core Insights - Xeriant, Inc. is undergoing a strategic transformation similar to that of SMX, aiming to enhance its innovation capabilities and commercial readiness through the establishment of the Factor X Research Group [1][2][12] - The new organizational structure is designed to accelerate the development and deployment of advanced technologies across various sectors, including aerospace and AI [3][4][18] Group 1: Organizational Changes - The appointment of Brig. Gen. (Ret.) Blaine D. Holt as president of Factor X signifies a shift towards a more coordinated and efficient innovation engine [1][5] - Factor X is modeled after Lockheed Martin's Skunk Works, focusing on reducing barriers to innovation and fostering cross-disciplinary collaboration [3][11] - The restructuring reflects broader market trends favoring specialized innovation groups over traditional R&D models [12] Group 2: Strategic Goals - Factor X aims to integrate advanced materials, aerospace innovations, and AI-driven tools into scalable, revenue-generating deployments [8][18] - The company plans to execute multi-sector expansion across industries such as aerospace, defense, construction, and infrastructure [18] - Xeriant is pursuing targeted acquisitions in AI, quantum computing, and data science to enhance its technological capabilities [18] Group 3: Comparison with Other Companies - Xeriant's approach mirrors the successful transformation of SMX, which established a network of partnerships to create a repeatable system for scaling technology [2][7] - The company also draws parallels with Palantir Technologies, which centralized its engineering talent to deploy complex systems effectively [9][10][11] - Both SMX and Palantir demonstrate that credibility and success come from creating integrated, scalable systems rather than focusing on individual products [7][8]

UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) hereby informs that meeting of holders of notes of the Company, ISIN LT0000405938 (hereinafter, the “Notes”), dated 28 November 2025 approved the following proposals, provided by the Company (hereinafter, the “Proposals”): 1. The Maturity Date of the Notes is prolonged from 14 December 2025 to 15 June 2026. 2. The Interest Rate of the Notes is increased from 5.00% per annum to 8.50% per annum, as from 15 December 2025 and until the ...

WASHINGTON, Nov. 28, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced the establishment of a new Photonics Chair at the University of Witwatersrand, Johannesburg (Wits University), through an endowment under a three-year donation agreement. Dr. Angela Dudley has been named as the inaugural incumbent of the new Photonics ...

Core Insights - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," which has led to a USD $700 million lawsuit [2][4]. - The investigative series aired by CTV News highlights the impact of stock spoofing on retail investors and the broader implications for market integrity [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in reversing nerve cell degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their trading platforms [4]. - The company aims to use the exposure from the lawsuit to protect other firms and investors from similar experiences of market manipulation [4].

Core Viewpoint - Pasithea Therapeutics Corp. has announced a public offering of 80 million shares at $0.75 per share, aiming to raise approximately $60 million to support its ongoing research and development efforts [1][3]. Group 1: Offering Details - The public offering consists of 80,000,000 shares of common stock or pre-funded warrants at an offering price of $0.75 per share [1]. - The offering is led by healthcare-focused investors, including Vivo Capital, Janus Henderson Investors, and others [1][8]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be around $60 million before deducting fees and expenses [3]. - The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions [3]. - Following the offering, the company's cash runway is projected to extend through at least the first half of 2028 [3][8]. Group 3: Company Overview - Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a macrocyclic MEK inhibitor for treating neurofibromatosis type 1-associated plexiform neurofibromas [6]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients and a Phase 1/1b trial in adult patients with NF1-associated plexiform neurofibromas [6].